Weekly Recap | GENSCRIPT BIO -8.92%, pullback outpacing the Hang Seng Index

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

GenScript Biotech (1548.HK) fell 8.92% this week to close at HK$27.76, underperforming the Hang Seng Index’s 5.65% decline by about 3.27 percentage points. The stock swung between HK$28.36 and HK$31.60 from Monday to Wednesday, then dropped sharply on Thursday to HK$27.32 before settling at HK$27.76. No major catalyst emerged this week.

Analyst Ratings

Seven brokers cover the stock: five rate it buy and two rate it overweight, with no hold or sell ratings. The consensus rating is strong buy, with a consensus target price of HK$45.44, roughly 63.7% above the latest close. Targets range from HK$29.999 to HK$87.98, showing wide dispersion. The stock ranks 8th out of 12 names in the life sciences tools and services industry.

The Week Ahead

GenScript Biotech is set to report fiscal Q3 2026 results after market close on Monday, 23 November 2026. The full-year 2026 annual results are due on 15 March 2027, with consensus estimates at HK$0.0502 EPS and HK$7.047 billion in revenue.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.